Seminar: Prof. Tanja de Gruijl

Therapeutic modulation of the microenvironment in tumor-draining lymph nodes

25 March 2015 15:00 hrs. - 16:00 hrs.
Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route 289
Therapeutic modulation of the microenvironment in tumor-draining lymph nodes

Prof. Tanja de Gruijl Department of Medical Oncology, VU University medical center – Cancer Center Amsterdam, The Netherlands


Dr. Ghaith Bakdash, Dept. of Tumor Immunology, Theme Cancer development and immune defence

25-03-2015 15:00:0025-03-2015 16:00:00Europe/AmsterdamTherapeutic modulation of the microenvironment in tumor-draining lymph nodes Figdor Lecture Theatre, 8th floor RIMLS Building, Geert Grooteplein 26-28, route

Remarks / more information:

undefinedTanja de Gruijl heads the Immunotherapy and Immune-monitoring Lab at the VUmc Cancer Center in Amsterdam, where she has been appointed Professor of Translational Tumor Immunology and holds a Fenna Diemer Lindeboom Chair. She has over 20 years of experience in the field of tumor immunology with some 140 peer-reviewed publications to her name. Her research ranges from preclinical topics to immune-monitoring of Phase I-III clinical trials. She has close collaborations with various departments within the VUmc, with international academic institutes, and with biotech and pharmaceutical companies.

Her main line of research is the in vivo targeting and modulation of dendritic cells (DC) through molecular targeting and local cytokine or TLR-L administration. Further topics of research include tumor-mediated immune suppression, control of DC differentiation, the effects of cytostatic drugs on DC development and functionality, and the immune potentiation of tumor-draining lymph nodes and  the tumor microenvironment.

Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF) and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She has managed and supervised the research that has led to the allogeneic DC vaccination platform technology of the VUmc spin-off company DCPrime BV, of which she is now scientific advisor. She is a member of the Grant Review committee of the US-based Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society (KWF), Associate Editor of Cancer Immunology Research, and currently chairs the Dutch Tumor Immunology Working Party.

Key publications:

  • Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with Prostate GVAX and ipilimumab. J Immunother Cancer. 2:31-42, 2014.
  • High and Interrelated Rates of PD-L1+CD14+ Antigen-presenting Cells and Regulatory T cells mark the Micro environment of Metastatic Lymph Nodes from Patients with Cervical Cancer. Cancer Immunol Res. 3:1, 2015.
  • Arming the Melanoma Sentinel Lymph Node through local administration of CpG-B and GM-CSF: recruitment and activation of BDCA3/CD141+ Dendritic Cells and enhanced cross-presentation. Cancer Immunol Res. ePub ahead of print, 2015


<< back to all events